-
@ Layer3.news
2025-06-17 17:52:07
nostr:nprofile1qy3hwumn8ghj7un9d3shjtt5v4ehgmn9wshxkwrn9ekxz7t9wgejumn9waesqgr8g2hyzql5lt4cxfjdj40hgtu6vydvsqvsesqy8canygcce3lwvyyapkyy
H.C. WAINWRIGHT SEES BILLION DOLLAR POTENTIAL IN UROGEN’S NEW THERAPY
https://s.yimg.com/ny/api/res/1.2/0Dz8_NtTfFlc0D.9zkhgNg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/123b08d23dbbae46a053475dd60eed2e
--
✍️ UroGen Pharma Ltd. (NASDAQ:URGN) has been upgraded to a 'Buy' rating by analysts at H.C. Wainwright, with a price target of $50.00, following regulatory approval of Zusduri.
--
👉 Analysts at H.C. Wainwright upgrade UroGen Pharma Ltd. (NASDAQ:URGN) to 'Buy' rating
👉 Price target of $50.00
👉 Regulatory approval of Zusduri
👉 Potential to rise even further
👉 Launch of new product aimed at non-muscle invasive bladder cancer
👉 Expected to generate $1 billion in sales by 2026
--
#NewJersey #business
--
nostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqy3hwumn8ghj7un9d3shjtt5v4ehgmn9wshxkwrn9ekxz7t9wgejumn9waesqgqsmrn885m5kk44fd3ns3naee69xg9kj464h9fuh3tt45sff8py2uy7meac